Categories

Industry News

Blood Testing Market Surpasses USD 2 Billion in 2016

By Labmedica International staff writers
16 Jun 2017

Image: The global market for blood testing and typing products reached USD 2.6 billion in 2016 (Photo courtesy of iStock).The global market for blood testing and typing products used in blood banking/donations of pooled blood reached USD 2.6 billion in 2016, although blood banking is not a fast-growing market and tends to grow only when new diseases are added to testing menu. These are the latest findings of Kalorama Information (New York, NY, USA), an independent medical market research firm.

In its study of the testing markets amidst increased vigilance by U.S. health authorities and cases of Zika and other diseases, Kalorama found three common types of tests related to blood banking:

Immunoassays for HIV, hepatitis B, hepatitis C and syphilis are routinely used to test blood units for blood borne infectious agents. In Latin America, all blood banks also screen donated units for Chagas disease while in some developing countries, blood banks undertake additional screening for Dengue fever and malaria, which are common and deadly in several tropical nations.

Blood grouping and typing reagents and instruments are used by blood transfusion services, hospital and private blood banks and hospital laboratories that prepare blood units for transfusion to patients. Blood bank lab systems require blood tracking to avoid the possibility of the serious error of administering the wrong blood type to a patient.

Nucleic acid testing (NAT) allows blood banks to detect viral contamination, including West Nile Virus, HIV and hepatitis C, sooner and stop them from slipping into blood transfusions, thus making NAT an integral part of efforts to make blood transfusions safer. An estimated 53 million units of blood are screened using NAT. The commonly used NAT assays detect HIV-1 RNA, HCV RNA, HBV DNA, and West Nile Virus (WNV) RNA, and are used to test for West Nile virus, HIV and HCV in almost all the blood drawn in North America, Europe and Japan.

“Although no dramatic change in the testing industry is expected, new guidelines and disease concerns make it a worthwhile time for business planners to revisit test market assumptions,” said Bruce Carlson, Publisher of Kalorama Information.

Related Links:
Kalorama Information



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

15 Aug 2017
Philips Sells MR-HIFU Business to Profound Medical
Royal Philips has completed the sale of its Sonalleve MR-HIFU business to Profound Medical Inc.
Read More
07 Aug 2017
Philips Sells MR-HIFU Business to Profound Medical
Royal Philips has completed the sale of its Sonalleve MR-HIFU business to Profound Medical Inc.
Read More
07 Aug 2017
Mexico IVD Market Valued at USD 405 Million for 2016
Mexico's in vitro diagnostic (IVD) market is valued at USD 405 million for 2016, making it the second largest in Latin America, and is considered moderate in its regulatory process and foreign investment opportunities. These are the latest findings of Kalorama Information, an independent medical market research firm.
Read More
01 Aug 2017
DiaSorin to Acquire Siemens' ELISA Immunodiagnostics Business
DiaSorin S.p.A. has entered into an agreement to acquire Siemens Healthineers’ micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.
Read More
24 Jul 2017
Siemens to Acquire Blood Gas Subsidiary of Alere
Siemens Healthineers, the separately managed healthcare business of Siemens AG, has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. that develops and provides point-of-care (POC) blood diagnostic systems for healthcare enterprises.
Read More
24 Jul 2017
Quidel to Acquire Alere Triage Assets
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has entered into definitive agreements to acquire the Triage MeterPro cardiovascular (CV) and toxicology assets (“Triage business”) and the B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter analyzers (“BNP business”) from Alere Inc. These products are being divested in order to obtain antitrust approvals required for Abbott’s pending acquisition of Alere.
Read More
24 Jul 2017
Philips Acquires TomTec Imaging Systems
Royal Philips has signed an agreement to acquire TomTec Imaging Systems GmbH, a provider of intelligent image analysis software, especially for diagnostic ultrasound. The acquisition is expected to strengthen Philips’ position in cardiac ultrasound, and support the company’s further expansion in other clinical areas, such as obstetrics and gynecology (OB/GYN).
Read More
17 Jul 2017
Global Clinical Lab Services Market to Reach USD 327 Billion by 2025
The global clinical laboratory services market is expected to reach USD 327 billion by 2025, driven by the improvement and implementation of informatics and automated data management solutions to perform seamless operations. The competition among medical device manufacturers for the development of clinical chemistry analyzers that can provide rapid results is also expected to aid the market growth. However, sample preparation and running it through experimental protocols with enhanced productivity still remains a challenge for labs.
Read More
11 Jul 2017
Global Hematology Analyzer Market to Surpass USD 2 Billion by 2024
The global hematology analyzer market is expected to surpass USD 2 billion, driven by the introduction of new and innovative products & methods, with sales of 6-part differential analyzers to register the fastest growth and hospitals to account for the highest share.
Read More
Copyright © 2000-2017 TradeMed.com. All rights reserved. | Terms And Conditions